Aberrantly activated AREG–EGFR signaling is required for the growth and survival of CRTC1–MAML2 fusion-positive mucoepidermoid carcinoma cells
Open Access
- 26 August 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 33 (29), 3869-3877
- https://doi.org/10.1038/onc.2013.348
Abstract
Salivary gland tumors (SGT) are a group of highly heterogeneous head and neck malignancies with widely varied clinical outcomes and no standard effective treatments. The CRTC1–MAML2 fusion oncogene, encoded by a recurring chromosomal translocation t(11;19)(q14-21;p12-13), is a frequent genetic alteration found in >50% of mucoepidermoid carcinomas (MEC), the most common malignant SGT. In this study, we aimed to define the role of the CRTC1–MAML2 oncogene in the maintenance of MEC tumor growth and to investigate critical downstream target genes and pathways for therapeutic targeting of MEC. By performing gene expression analyses and functional studies via RNA interference and pharmacological modulation, we determined the importance of the CRTC1–MAML2 fusion gene and its downstream AREG–EGFR signaling in human MEC cancer cell growth and survival in vitro and in vivo using human MEC xenograft models. We found that CRTC1–MAML2 fusion oncogene was required for the growth and survival of fusion-positive human MEC cancer cells in vitro and in vivo. The CRTC1–MAML2 oncoprotein induced the upregulation of the epidermal growth factor receptor (EGFR) ligand Amphiregulin (AREG) by co-activating the transcription factor CREB, and AREG subsequently activated EGFR signaling in an autocrine manner that promoted MEC cell growth and survival. Importantly, CRTC1–MAML2-positive MEC cells were highly sensitive to EGFR signaling inhibition. Therefore, our study revealed that aberrantly activated AREG–EGFR signaling is required for CRTC1–MAML2-positive MEC cell growth and survival, suggesting that EGFR-targeted therapies will benefit patients with advanced, unresectable CRTC1–MAML2-positive MEC.Keywords
This publication has 32 references indexed in Scilit:
- CREB and the CRTC co-activators: sensors for hormonal and metabolic signalsNature Reviews Molecular Cell Biology, 2011
- A Reappraisal of the MECT1/MAML2 Translocation in Salivary Mucoepidermoid CarcinomasThe American Journal of Surgical Pathology, 2010
- Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glandsBritish Journal of Cancer, 2010
- Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neckProceedings of the National Academy of Sciences of the United States of America, 2009
- Unfavorable prognosis of CRTC1‐MAML2 positive mucoepidermoid tumors with CDKN2A deletionsGenes, Chromosomes and Cancer, 2009
- The coactivator CRTC1 promotes cell proliferation and transformation via AP-1Proceedings of the National Academy of Sciences of the United States of America, 2009
- New insights into the nature of Warthin’s tumourJournal of Oral Pathology & Medicine, 2008
- Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type CancersClinical Cancer Research, 2008
- Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: A case report and review of literatureJournal of Medical Case Reports, 2008
- Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor ReceptorClinical Cancer Research, 2007